• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • NMPA Initiates Working Plan for Medical Device Sampling Inspection

NMPA Initiates Working Plan for Medical Device Sampling Inspection

Sampling Inspection
Wednesday, 03 June 2020 / Published in Medical Device

NMPA Initiates Working Plan for Medical Device Sampling Inspection

On 13.05.2020, the NMPA (National Medical Products Administration) published a notice (No.46-2020) with further details on the recently implemented medical device sampling inspection requirements. It addresses the important work items for inspection, reinspection, objections and appeals, and other requirements based on the administrative measures (No.09-2020) released on 13th March. A high level summary of the measures is set out below.

Inspection
All provincial MPAs (Medical Product Administration) and the National Institutes for Food and Drug Control should refer to detailed requirements set out behind Annex 1 and Annex 2 of the Notice for conducting sampling inspections on medical devices in China. Both of the Annexes outline the specific regulatory standards, inspection items, and principles for determining the inspection results.

Reinspection
According to Rule 32 in the NMPA’s administrative measures (No.09-2020) for sampling inspection on medical devices, an application for an appeal reinspection can be made by the NMPA Legal Agent who is dissatisfied with the results of the inspection report. Such application must be made within 7 working days following the day on which the inspection report was received.

Objections & appeals
The application for an appeal reinspection must be submitted to the corresponding provincial MPA, in written form and should include any materials as proof, within 7 working days following the day on which the inspection report was received.

The respective provincial MPA should file a report within 2 working days following the day on which the application was received. The National Institutes for Food and Drug Control should receive a revalidation of the inspection results and suggestions from the local MPA within 15 working days.

Other requirements
According to Rule 30 in the NMPA’s administrative measures (No.09-2020) for sampling inspection on medical devices, if the NMPA Legal Agent claims that the sample product is not the same original product, the NMPA Legal Agent must submit any related materials to the respective local MPA as proof.

Also, the NMPA Legal Agent must submit the materials within 7 working days following the day on which the inspection report was received.

Read more from our prior news about the NMPA‘s administrative measures (No.09-2020) for sampling inspection on medical devices.

By Jacky Li. Contact Cisema to learn more.

Tagged under: Sampling Inspection

What you can read next

NMPA report on the registration of medical devices in 2013, 2014, 2015
Supervision and administration of medical devices
Supervision and administration of medical device – sampling inspections finds 12 product failures
CMDE Preps for AI Software to Soar in China

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP